Novartis Weighs Deal For Biotech Avidity To Boost Drug Pipeline - FT
ReutersAug 6, 2025 3:19 PM
Aug 6 (Reuters) -
NOVARTIS WEIGHS DEAL FOR BIOTECH AVIDITY TO BOOST DRUG PIPELINE - FT
Source text: https://tinyurl.com/3zp5hhxs
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
BoE August Rate Decision Commentary: Where Next for the Pound?
TradingKey - On 7 August 2025, the Bank of England (BoE) lowered its benchmark interest rate from 4.25% to 4%, aligning with broad market expectations. Notably, the decision sparked significant division within the committee, requiring two rounds of voting to pass.TradingKey
Fri, Aug 8
U.S. GDP, PCE, and Fed Rate Decision Commentary: Will U.S. Stocks Continue to Rise?
TradingKey - On 30–31 July 2025, the United States released its latest GDP and PCE data, while the Federal Reserve announced its interest rate decision during the same period.TradingKey
Fri, Aug 1
Ethereum Price Prediction: Will ETH Extend the Rally? What’s the Future Trend?
Ethereum's impressive 2025 rally has been largely fueled by inflows from spot ETFs and a surge in institutional holdings, signaling growing confidence in its role as a core asset in the crypto market. However, to officially confirm the start of a new bull cycle, ETH must break above the critical $4,TradingKey
Wed, Jul 23
What Is the GENIUS Act, and Why Is Its Impact Comparable to a Bitcoin Spot ETF?
The GENIUS Act represents a groundbreaking federal regulatory framework for U.S. stablecoins, defining legal issuance standards, oversight responsibilities, consumer protections, and reserve requirements. While its primary objective is to advance U.S. financial interests, it will significantly shaTradingKey
Fri, May 30
